
usd feb pm et
summari global medic product servic compani provid hospit suppli renal
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
inc lift
target price base
multipl vs bax rang
ep estim
continu work complet
intern investig announc late
octob improperli record
releas result soon
reason practic later
end first quarter sale
increas billion slightli
expect america grew
constant currenc cc emea grew cc
growth line
expect adjust oper
margin reflect
approxim basi point yoy margin
expans midpoint keep
ep estim initi
ep huang cfa
risk assess reflect oper highli
competit busi character rapid
technolog chang new market entrant
addit busi entail regulatori
reimburs risk well liabil risk
malfunct product off-set view
health care product larg immun econom
fiscal year end dec ep estim base cfra
oper earn histor earn report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc provid broad portfolio essenti healthcar
product includ acut chronic dialysi therapi steril intraven iv solut infus
system devic parenter nutrit therapi inhal anesthet gener inject
pharmaceut surgic hemostat sealant product baxter ad capabl
product essenti gener inject medicin acquisit clari inject limit
clari compani global footprint critic natur product servic play key role
expand access healthcar emerg develop countri product use
hospit kidney dialysi center nurs home rehabilit center doctor offic patient
home physician supervis decemb baxter manufactur product
countri sold countri
chang commerci structur report financi perform base follow
geograph segment america north south america emea europ middl east africa
apac asia-pacif revenu gener outsid unit state geograph
expans remain compon compani strategi gener approxim
revenu outsid unit state america made total revenu emea
apac
global busi unit renal care acut therapi medic deliveri
pharmaceut nutrit advanc surgeri largest unit renal care billion
revenu medic deliveri billion pharmaceut billion combin
three unit compris revenu
renal includ sale periton dialysi hemodialysi machin well addit
dialysi therapi servic medic deliveri includ sale iv therapi infus pump
administr set drug reconstitut devic unit includ sale
compani premix oncolog drug platform inhal anesthesia critic care product
corpor strategi focus sever key object success execut long-term
strategi achiev sustain growth deliv enhanc stockhold valu baxter diversifi
broad portfolio medic product treat life-threaten acut chronic condit global
presenc core compon compani strategi achiev object compani
focus three strateg factor part pursuit industri lead perform optim
core portfolio global oper excel focus streamlin cost structur enhanc
oper effici follow disciplin balanc approach capit alloc
expect seek strateg acquisit help achiev goal make major
acquisit invest acquir clari inject limit clari produc
gener inject medicin anesthesia analges million
competit landscap although lead posit key market must still contend
signific competit pressur market baxter face substanti competit
segment intern domest healthcar pharmaceut compani provid
size competitor often differ across busi competit primarili focus
cost-effect price servic product perform technolog innov
increas consolid compani custom base competitor continu result
price market pressur
major develop octob announc self-initi intern investig
intra-compani transact use foreign exchang rate accord
intra-compani transact question undertaken purpos gener foreign exchang
gain loss accord octob intern investig still earli
stage determin durat outcom said investig
juli spun-off biopharmaceut busi separ trade public compani
name baxalta oper result baxalta reflect discontinu oper
financi trend baxter global net sale total billion increas report
basi increas constant currenc basi sale total billion
increas report basi constant currenc compar sale unit
state total billion increas compar prior year earn per share
vs prior year flow oper increas year-over-year billion
net debt total capit ratio histor low decemb
presid
pharmaceut
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc decemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neutral expect
compani continu achiev robust organ
growth mid- high-single-digit revenu
growth driven new product
data provid estim world-wide medic
devic sale grow
time think potenti slowdown
macroeconom growth could pressur
industri driver yet sub-industri
includ mani product area
histor recession-resist
equip use non-elect procedur
gener see posit long-term
fundament medic devic manufactur
includ increas global demand
popul rise outlay
result steadi flow innov product
revenu growth
polit regulatori perspect
medic devic industri larg avoid
scrutini unlik area health
drug maker fact medic devic tax
final repeal decemb remov
signific risk sale devic maker
think industri continu
dwindl industri come back
favor especi sinc valuat health
rel
forward price-to-earn basi think
higher valuat sub-industri
mostli warrant margin expans
revenu growth opportun associ
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much
commentari around introduct mdr
reason believ new
regul could neg impact
industri exampl juli
submit letter world trade
organ request mdr ivdr
delay three year also novemb
associ critic slow piecem
implement new regulatori
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
expect industri earn rise
low-double-digit percentag driven sale
new product command higher
margin project industri oper
ebit margin
estim margin
 health equip
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
ep estim multipl compar peer
low-end rang sinc juli baxalta
divestitur rais ep estim start
post ep vs beat consensu estim
sale rose constant currenc slightli ahead expect
growth domest increas intern higher sale
support greater demand bax renal advanc
surgeri acut therapi busi pharmaceut growth benefit
increas demand anesthesia critic care product think
secular long-term trend posit compani maintain
above-p valuat believ must demonstr abil innov
futur pipelin kevin huang cfa angelo zino cfa
inc lower target
ep estim multipl low-end
rang sinc juli baxalta divestitur ep
vs higher estim rais ep
lower ep earn
call manag highlight sale large-volum iv solut
spike first month year lead inventori destock across
custom result lower sale growth guidanc
previou guidanc sale increas organ
billion growth constant currenc cc america
growth cc emea declin cc apac expect
improv medic deliveri clinic nutrit segment
segment experienc low-single-digit cc sale declin /kevin
analyst research note compani news
pm et cfra keep hold opinion share
lift target price base
multipl vs bax rang
ep estim continu work complet
intern investig announc late octob improperli record
intra-compani transact result releas
result soon reason practic later end
first quarter sale increas billion
slightli expect america grew constant currenc cc
emea grew cc apac grew cc compani expect sale growth
line expect adjust oper margin
reflect approxim basi point yoy margin
expans midpoint keep ep estim
initi ep /kevin huang cfa
et cfra keep hold opinion share
lift target price base
multipl three-year averag ep estim
due record intra-compani transact use foreign
exchang rate accord recent began
intern investig transact result expect
file time manner intra-compani
transact question undertaken purpos gener foreign
exchang gain loss accord intern investig still
earli stage determin durat outcom said
investig share trade approxim morn
news revenu increas organ billion slightli short
consensu expect maintain ep estim
conduct intern investig /kevin huang cfa
pm et cfra keep hold opinion share
lift target price base
multipl averag ep
rais ep estim maintain ep
post ep vs exceed estim
growth driver includ periton dialysi continu
renal replac therapi intraven infus system hemostat
sealant certain gener pharmaceut world-wide revenu roughli
flat year-over-year billion organ basi
exceed consensu expect sale decreas
billion intern sale increas constant currenc basi
billion respons trump administr initi
increas home dialysi made plan depend initi final
form make invest million potenti new facil
pm et cfra keep hold opinion share
lift target price base
multipl ep estim multipl
compar peer near averag forward pe rang
rais ep estim
ep post ep vs beat
consensu estim lower-than-expect tax rate
decreas share count sale declin constant currenc
expect sale decreas intern
sale increas constant currenc basi advanc surgeri
pharmaceut busi unit perform well constant currenc sale
grew respect laggard clinic nutrit
medic deliveri busi constant currenc declin
respect overal compani perform slightli better expect
pm et cfra keep hold opinion share
increas target
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
